Molecular Partners is progressing its Phase 1/2a clinical trial of MP0712, a Radio-DARPin therapeutic targeting DLL3 for small cell lung and neuroendocrine cancers, with patient dosing ongoing at five US centers. Initial clinical data are expected within months, with comprehensive safety and efficacy results anticipated in 2027. The company is also expanding its pipeline with new Radio-DARPins, including MP0726 targeting mesothelin, planned for first-in-human imaging later in 2026, and aims to file two INDs in 2027. These developments highlight the versatility of their DARPin platform in delivering alpha-emitting isotopes for targeted cancer therapy.
Computeshare PTE. LTD., based in Singapore, announced the launch of its global membership ecosystem, with a closed beta set for July 16, 2026, in China. The platform integrates advanced AI services and a mature T3+T4 computing infrastructure to suppo...
During week 27 of 2026 (June 29 to July 3), Sampo Oyj bought back a total of 151,313 of its A-shares across multiple markets at an average price of €9.14 per share. This buyback is part of a larger program authorized by the company's annual general m...
Novartis has agreed to acquire Myricx Bio, a UK-based oncology company developing novel antibody-drug conjugates (ADCs), for up to $1.5 billion including $1.1 billion upfront. This acquisition combines Novartis's oncology expertise with Myricx Bio's ...
Novartis has agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront, to enhance its oncology portfolio with Myricx's novel antibody-drug conjugate (ADC) payloads. Myricx Bio specializes in a first-in-class...
The QAIAx AI City Hall Project has launched the world's first federally registered clinical trial for an AGI-governed smart city, emphasizing built-in privacy by anonymizing personal data. This project introduces a new AI technology and compliance pa...
